A significant share of patients with phenylalanine hydroxylase (PAH) deficiency benefits
from pharmacological doses of tetrahydrobiopterin (BH 4 ), the natural PAH cofactor. …

The discovery of a pharmacological treatment for phenylketonuria (PKU) raised new questions
about function and dysfunction of phenylalanine hydroxylase (PAH), the enzyme deficient …

Background In phenylketonuria, genetic heterogeneity, frequent compound heterozygosity,
and the lack of functional data for phenylalanine hydroxylase genotypes hamper reliable …

Pahenu1 is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase
deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo | …

Almost 2 years into the pandemic and with vaccination of children significantly lagging behind
adults, long-term pediatric humoral immune responses to SARS-CoV-2 are understudied. …

Protein misfolding with loss-of-function of the enzyme phenylalanine hydroxylase (PAH) is
the molecular basis of phenylketonuria in many individuals carrying missense mutations in …

Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA
dehydrogenase (GCDH) deficiency. The high number of missense variants associated with the …

Metabolic control of phenylalanine concentrations in body fluids is essential for cognitive
development and executive function. The hepatic phenylalanine hydroxylating system is …

Phenylketonuria (PKU), an autosomal recessive disease with phenylalanine hydroxylase (PAH)
deficiency, was recently shown to be a protein misfolding disease with loss-of-function. It …

SARS-CoV-2 is still a major burden for global health despite effective vaccines. With the
reduction of social distancing measures, infection rates are increasing in children, while data on …